Elevation Oncology, Inc.
ELEVNASDAQHealthcare
$0.37
$-0.01(-2.12%)
Market Cap$21627309
P/E Ratio—
52W High$3.09
52W Low$0.221
Elevation Oncology, Inc. (ELEV) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ELEV · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2025Report Date: Aug 5, 2025EPS Actual
-$0.18
Est. -$0.26 · +30.8%
Revenue
—
Fiscal Period
Q3 FY2025
FY ends December
Report Date
Aug 5, 2025
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
ELEV reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.11
Rev. $0.17B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.11
Rev. Est.$0.17B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q3 FY2025 | Aug 5, 2025 | -$0.26 | -$0.18 | +30.8% | — | — | — |
| ▼ Q2 FY2025 | May 15, 2025 | -$0.20 | -$0.24 | -20.0% | — | — | — |
| ▲ Q1 FY2025 | Mar 6, 2025 | -$0.22 | -$0.18 | +18.2% | — | — | — |
| ▼ Q4 FY2024 | Nov 6, 2024 | -$0.20 | -$0.22 | -10.0% | — | — | — |
| ▲ Q3 FY2024 | Aug 6, 2024 | -$0.23 | -$0.18 | +21.7% | — | — | — |
| ▼ Q2 FY2024 | May 2, 2024 | -$0.21 | -$0.23 | -9.5% | — | — | — |
| ▲ Q1 FY2024 | Mar 6, 2024 | -$0.21 | -$0.19 | +9.5% | $0.00B | — | — |
| ▲ Q4 FY2023 | Nov 2, 2023 | -$0.34 | -$0.25 | +26.5% | — | — | — |
Q3 FY2025
Aug 5, 2025Beat
EPS Actual
-$0.18
EPS Est.
-$0.26
EPS Surpr.
+30.8%
Revenue
—
Q2 FY2025
May 15, 2025Miss
EPS Actual
-$0.24
EPS Est.
-$0.20
EPS Surpr.
-20.0%
Revenue
—
Q1 FY2025
Mar 6, 2025Beat
EPS Actual
-$0.18
EPS Est.
-$0.22
EPS Surpr.
+18.2%
Revenue
—
Q4 FY2024
Nov 6, 2024Miss
EPS Actual
-$0.22
EPS Est.
-$0.20
EPS Surpr.
-10.0%
Revenue
—
Q3 FY2024
Aug 6, 2024Beat
EPS Actual
-$0.18
EPS Est.
-$0.23
EPS Surpr.
+21.7%
Revenue
—
Q2 FY2024
May 2, 2024Miss
EPS Actual
-$0.23
EPS Est.
-$0.21
EPS Surpr.
-9.5%
Revenue
—
Q1 FY2024
Mar 6, 2024Beat
EPS Actual
-$0.19
EPS Est.
-$0.21
EPS Surpr.
+9.5%
Revenue
$0.00B
Q4 FY2023
Nov 2, 2023Beat
EPS Actual
-$0.25
EPS Est.
-$0.34
EPS Surpr.
+26.5%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.17 | $-0.17 | $-0.17 | 1 |
| Q3 FY2027 | $-0.17 | $-0.17 | $-0.17 | 1 |
| Q2 FY2027 | $-0.14 | $-0.14 | $-0.14 | 1 |
| Q1 FY2027 | $-0.14 | $-0.14 | $-0.14 | 1 |
| Q4 FY2026 | $-0.16 | $-0.16 | $-0.16 | 1 |
| Q3 FY2026 | $-0.15 | $-0.15 | $-0.15 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q3 FY2025 | Aug 5, 2025 | +30.8% | $0.37 | — | — |
| ▼ Q2 FY2025 | May 15, 2025 | -20.0% | $0.34 | $0.30 | -12.24% |
| ▲ Q1 FY2025 | Mar 6, 2025 | +18.2% | $0.51 | $0.51 | +0.16% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -10.0% | $0.56 | $0.55 | -1.79% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +21.7% | $2.13 | $0.78 | -63.37% |
| ▼ Q2 FY2024 | May 2, 2024 | -9.5% | $4.00 | $3.82 | -4.50% |
| ▲ Q1 FY2024 | Mar 6, 2024 | +9.5% | $4.67 | $4.67 | +0.00% |
| ▲ Q4 FY2023 | Nov 2, 2023 | +26.5% | $0.44 | $0.44 | +0.00% |
Q3 FY2025—
Report Date
Aug 5, 2025
EPS Beat/Miss
+30.8%
Price Before
$0.37
Price After
—
Q2 FY2025-12.24%
Report Date
May 15, 2025
EPS Beat/Miss
-20.0%
Price Before
$0.34
Price After
$0.30
Q1 FY2025+0.16%
Report Date
Mar 6, 2025
EPS Beat/Miss
+18.2%
Price Before
$0.51
Price After
$0.51
Q4 FY2024-1.79%
Report Date
Nov 6, 2024
EPS Beat/Miss
-10.0%
Price Before
$0.56
Price After
$0.55
Q3 FY2024-63.37%
Report Date
Aug 6, 2024
EPS Beat/Miss
+21.7%
Price Before
$2.13
Price After
$0.78
Q2 FY2024-4.50%
Report Date
May 2, 2024
EPS Beat/Miss
-9.5%
Price Before
$4.00
Price After
$3.82
Q1 FY2024+0.00%
Report Date
Mar 6, 2024
EPS Beat/Miss
+9.5%
Price Before
$4.67
Price After
$4.67
Q4 FY2023+0.00%
Report Date
Nov 2, 2023
EPS Beat/Miss
+26.5%
Price Before
$0.44
Price After
$0.44
Avg Beat Reaction-15.80%
Avg Miss Reaction-6.18%
Beat Rate5 / 8 quarters
Largest Move-63.37% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ELEV ends December
Elevation Oncology, Inc. (ELEV) most recently reported earnings on August 5, 2025 for Q3 FY2025, posting EPS of $-0.18 — beating the analyst consensus of $-0.26 by +30.8%. The next ELEV earnings date is expected around September 1, 2026.
Each quarter, investors track ELEV earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ELEV revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ELEV's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ELEV earnings · 5 questionsElevation Oncology, Inc.'s next earnings report is expected around September 1, 2026. ELEV typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ELEV historically reports after market close (AMC).
ELEV earnings datewhen is ELEV earningsELEV next earnings datewhen does ELEV report earningsELEV earnings calendar
▸ Source: FMP · Elevation Oncology, Inc. SEC filings · US GAAP · Elevation Oncology, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026